Insider Sale: Director Gerard Holthaus Sells Shares of FTI Consulting Inc (FCN)

In this article:

On May 7, 2024, Director Gerard Holthaus sold 1,492 shares of FTI Consulting Inc (NYSE:FCN) as reported in a recent SEC Filing. This transaction is part of a series of insider activities noted over the past year, characterized by 20 insider sells and only 1 insider buy.

FTI Consulting Inc is a global business advisory firm that provides multidisciplinary solutions including corporate finance and restructuring, economic consulting, forensic and litigation consulting, technology, and strategic communications.

On the date of the sale, shares of FTI Consulting Inc were priced at $221.14. The company holds a market cap of approximately $7.84 billion. The price-earnings ratio of the company stands at 25.54, which is above the industry median of 17.93.

The GF Value of FTI Consulting Inc is $209.59, leading to a price-to-GF-Value ratio of 1.06, indicating that the stock is Fairly Valued.

Insider Sale: Director Gerard Holthaus Sells Shares of FTI Consulting Inc (FCN)
Insider Sale: Director Gerard Holthaus Sells Shares of FTI Consulting Inc (FCN)

The insider transaction trends and the valuation metrics provide a broader context for the insider's recent stock sale. The GF Value is derived from historical trading multiples, an adjustment factor based on past performance, and future business performance estimates.

Insider Sale: Director Gerard Holthaus Sells Shares of FTI Consulting Inc (FCN)
Insider Sale: Director Gerard Holthaus Sells Shares of FTI Consulting Inc (FCN)

This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.

This article first appeared on GuruFocus.

Advertisement